We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
If You Invested $1000 in DexCom a Decade Ago, This is How Much It'd Be Worth Now
Read MoreHide Full Article
How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across sectors and industries as well.
Another thing that can drive investing is the fear of missing out, or FOMO. This particularly applies to tech giants and popular consumer-facing stocks.
What if you'd invested in DexCom (DXCM - Free Report) ten years ago? It may not have been easy to hold on to DXCM for all that time, but if you did, how much would your investment be worth today?
DexCom's Business In-Depth
With that in mind, let's take a look at DexCom's main business drivers.
San Diego, CA-based DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems (CGM). These are for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients.
A key element of DexCom’s monitoring system technology is the continuous measure of patient's blood glucose level and transmission of that information to a small cell phone-sized receiver in real time. The company’s monitoring systems aim to provide real-time continuous blood glucose values, trend data and alerts to assist patients in managing their blood glucose levels.
Going by an article of Research and Markets, the blood glucose monitoring devices market is expected to witness a CAGR of over 9% between 2018 and 2024.
2020 at a Glance
For the full-year 2020, the company reported adjusted EPS of $3.10, up 68.5% from 2019. Full-year 2020 revenues came in at $1.93 billion, up 30.5% year over year.
Sensor & other revenue were $1.56 billion (81% of net revenues). Hardware revenues were $365.3 million (19% of net revenues).
Highlights
The first quarter of 2021 marked the company’s seventh consecutive quarter of revenue growth of $100 million or more. Moreover, the company witnessed about 40% global unit volume growth in the quarter, thereby indicating sustained customer growth in the business.
Bottom Line
Anyone can invest, but building a successful investment portfolio takes a combination of a few things: research, patience, and a little bit of risk. So, if you had invested in DexCom a decade ago, you're probably feeling pretty good about your investment today.
According to our calculations, a $1000 investment made in August 2011 would be worth $46,378.14, or a 4,537.81% gain, as of August 10, 2021. Investors should keep in mind that this return excludes dividends but includes price appreciation.
In comparison, the S&P 500 gained 278.02% and the price of gold went up -7.37% over the same time frame.
Analysts are anticipating more upside for DXCM.
DexCom exited the second quarter on a strong note, wherein both earnings and revenues beat the Zacks Consensus Estimate. Impressive contribution from the Sensor and other revenue segment, and domestic and international revenue growth were key catalysts. Expansion in both gross and operating margins is a positive. DexCom’s prospects in alternative markets such as the non-intensive diabetes management space are likely to provide it a competitive edge in the MedTech space. Apart from making continued advancements with respect to key strategic objectives, the company ended the quarter with new patient additions as well. Yet, DexCom faces stiff competition in the market for blood & glucose monitoring devices. Reimbursement risk and supply constraints are other headwinds. On a month-to-date basis, DexCom has underperformed its industry.
The stock has jumped 16.11% over the past four weeks. Additionally, no earnings estimate has gone lower in the past two months, compared to 8 higher, for fiscal 2021; the consensus estimate has moved up as well.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
If You Invested $1000 in DexCom a Decade Ago, This is How Much It'd Be Worth Now
How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across sectors and industries as well.
Another thing that can drive investing is the fear of missing out, or FOMO. This particularly applies to tech giants and popular consumer-facing stocks.
What if you'd invested in DexCom (DXCM - Free Report) ten years ago? It may not have been easy to hold on to DXCM for all that time, but if you did, how much would your investment be worth today?
DexCom's Business In-Depth
With that in mind, let's take a look at DexCom's main business drivers.
San Diego, CA-based DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems (CGM). These are for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients.
A key element of DexCom’s monitoring system technology is the continuous measure of patient's blood glucose level and transmission of that information to a small cell phone-sized receiver in real time. The company’s monitoring systems aim to provide real-time continuous blood glucose values, trend data and alerts to assist patients in managing their blood glucose levels.
Going by an article of Research and Markets, the blood glucose monitoring devices market is expected to witness a CAGR of over 9% between 2018 and 2024.
2020 at a Glance
For the full-year 2020, the company reported adjusted EPS of $3.10, up 68.5% from 2019. Full-year 2020 revenues came in at $1.93 billion, up 30.5% year over year.
Sensor & other revenue were $1.56 billion (81% of net revenues). Hardware revenues were $365.3 million (19% of net revenues).
Highlights
The first quarter of 2021 marked the company’s seventh consecutive quarter of revenue growth of $100 million or more. Moreover, the company witnessed about 40% global unit volume growth in the quarter, thereby indicating sustained customer growth in the business.
Bottom Line
Anyone can invest, but building a successful investment portfolio takes a combination of a few things: research, patience, and a little bit of risk. So, if you had invested in DexCom a decade ago, you're probably feeling pretty good about your investment today.
According to our calculations, a $1000 investment made in August 2011 would be worth $46,378.14, or a 4,537.81% gain, as of August 10, 2021. Investors should keep in mind that this return excludes dividends but includes price appreciation.
In comparison, the S&P 500 gained 278.02% and the price of gold went up -7.37% over the same time frame.
Analysts are anticipating more upside for DXCM.
DexCom exited the second quarter on a strong note, wherein both earnings and revenues beat the Zacks Consensus Estimate. Impressive contribution from the Sensor and other revenue segment, and domestic and international revenue growth were key catalysts. Expansion in both gross and operating margins is a positive. DexCom’s prospects in alternative markets such as the non-intensive diabetes management space are likely to provide it a competitive edge in the MedTech space. Apart from making continued advancements with respect to key strategic objectives, the company ended the quarter with new patient additions as well. Yet, DexCom faces stiff competition in the market for blood & glucose monitoring devices. Reimbursement risk and supply constraints are other headwinds. On a month-to-date basis, DexCom has underperformed its industry.
The stock has jumped 16.11% over the past four weeks. Additionally, no earnings estimate has gone lower in the past two months, compared to 8 higher, for fiscal 2021; the consensus estimate has moved up as well.